Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Libraries
  3. MIT Theses
  4. Doctoral Theses
  5. Quantitative analysis of signaling networks in proneural glioblastoma

Quantitative analysis of signaling networks in proneural glioblastoma

Thumbnail Image
Download
Name

921845520-MIT.pdf

Description
Full printable version
Size

15.28 MB

Format

Adobe PDF

Checksum (MD5)

d8aab7939269a3a3131fc1bdc519a719

Author(s)
Lescarbeau, Rebecca S. (Rebecca Susan)
Advisor(s)
Forest M. White.
Date Issued
2015
Publisher
Massachusetts Institute of Technology
Abstract
Glioblastoma (GBM) is the most common malignant form of brain cancer. Even with treatment including surgery, radiation, and temozolomide chemotherapy, the 1 year survival rate is only 35%. To identify specific mediators of GBM progression in a genetically engineered murine model of proneural GBM, we quantified signaling networks using mass spectrometry. We identified oncogenic signaling associated with the GBM model, such as increased phosphorylation of ERK1/2, P13K, and PDGFRA, relative to murine brain. Phosphorylation of CDK₁ Y₁₅, which causes G₂ /M cell cycle arrest, was measured to be the most differentially phosphorylated site, with a 14-fold increase in the tumors. We used syngeneic cell lines to investigate this checkpoint further and treated these cells with MK-₁₇₇₅, an inhibitor of Wee₁, the kinase responsible for phosphorylation of CDK₁ Y₁₅. MK-₁₇₇₅ treatment resulted in mitotic catastrophe of these cells, as measured by increased DNA damage, abnormal percentages of cells in cell cycle phases, and death by apoptosis. This response was abrogated by inhibiting CDK₁ with roscovitine, a CDK inhibitor, demonstrating the necessity of active CDK₁ for MK-₁₇₇₅ induced mitotic catastrophe. To assess the extensibility of targeting Wee₁ and the G₂/M checkpoint in GBM, we treated patientderived xenograft (PDX) cell lines with MK-₁₇₇₅. The response was more heterogeneous, but we measured decreased CDK₁ phosphorylation, increased DNA damage, and death by apoptosis. These results were validated in a flank GBM PDX model where treatment with MK-₁₇₇₅ increased mouse survival by 1.74-fold. We also quantified the signaling differences in our murine GBM model after treatment with sunitinib, an inhibitor of its driver receptor tyrosine kinase, PDGFRA. Treatment increased survival but lead to a morphological change causing a more invasive phenotype. Pro-migratory signaling was characterized by mass spectrometry, such as increased phosphorylation of Eno₁, ELMO₂, and tubulins. Invasion was further characterized in a lung cancer model where we identified signaling specific to different ligands that result in similar levels of invasion. We have demonstrated that unbiased, quantitative phosphotyrosine proteomics has the ability to reveal therapeutic targets in tumor models and signaling differences between treatments.
Description
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2015.
Cataloged from PDF version of thesis.
Includes bibliographical references.
Subjects
Biological Engineering.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
http://dspace.mit.edu/handle/1721.1/7582
Persistent DSpace Link
http://hdl.handle.net/1721.1/99055
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.